Johnson & Johnson yesterday notified employees it will consolidate the sales and marketing operations of two subsidiaries, Ortho Biotech and Centocor, leading to roughly 400 job cuts nationwide. The move is a response to the declining sales of a class of anemia drugs that includes Johnson & Johnson’s Procrit, a company spokesman said. Prescriptions for Procrit fell sharply last year after the Food and Drug Administration placed new safety warnings on the drugs, known as erythropoiesis-stimulating agents.
